复发缓解型多发性硬化患者接受皮下干扰素β-1a治疗时每日补充高剂量维生素D3的随机试验
SOLAR研究为II期随机双盲安慰剂对照试验,纳入229例接受皮下干扰素β-1a 44 μg每周三次且血清25(OH)D<150 nmol/L的复发缓解型多发性硬化患者,1:1随机接受安慰剂或口服高剂量维生素D3 14,007 IU/d。48周时高剂量维生素D3组NEDA-3比例为36.3%,与安慰剂组35.3%无统计学显著差异(OR 0.93,95%CI 0.53-1.63,p=0.80);探索性结局显示高剂量维生素D3组MRI联合唯一活动病灶发生率更低(IRR 0.68,95%CI 0.52-0.89,p=0.0045),T2病灶总体积较基线变化也有改善(平均秩差-0.074,p=0.035)。
要点
- 高剂量维生素D3添加治疗未显著提高48周NEDA-3比例(36.3% vs 35.3%,p=0.80)。
- 探索性MRI结局显示高剂量维生素D3可能减少新发MRI活动病灶。
- 研究提供Class II证据:补充胆钙化醇48周未促进NEDA-3状态。
核心结论
- 基于主要结局NEDA-3,SOLAR研究未确立高剂量维生素D3作为干扰素β-1a添加治疗的获益。
- 探索性结局提示高剂量维生素D3对复发缓解型多发性硬化患者新发MRI病灶可能有保护效应。
研究设计与样本
- II期随机双盲安慰剂对照试验(NCT01285401),2011年2月15日至2015年5月11日纳入229例患者。
- 纳入接受皮下干扰素β-1a 44 μg每周三次且血清25(OH)D<150 nmol/L的复发缓解型多发性硬化患者。
- 患者1:1随机接受皮下干扰素β-1a联合安慰剂(n=116)或联合口服高剂量维生素D3 14,007 IU/d(n=113)。
- 修订后的主要结局为48周时无疾病活动证据(NEDA-3)的患者比例。
主要发现
- 48周时高剂量维生素D3组36.3%患者达到NEDA-3,安慰剂组为35.3%,组间无统计学显著差异(OR 0.93,95%CI 0.53-1.63,p=0.80)。
- 与安慰剂相比,高剂量维生素D3组MRI联合唯一活动病灶发生率更低(IRR 0.68,95%CI 0.52-0.89,p=0.0045)。
- 高剂量维生素D3组T2病灶总体积较基线变化优于安慰剂组(平均秩差-0.074,p=0.035)。
关键数值与推荐
- 主要结局NEDA-3:高剂量维生素D3组36.3%,安慰剂组35.3%,OR 0.93(95%CI 0.53-1.63),p=0.80。
- MRI联合唯一活动病灶:IRR 0.68(95%CI 0.52-0.89),p=0.0045。
- T2病灶总体积较基线变化:平均秩差-0.074,p=0.035。
- 研究提供Class II证据:皮下干扰素β-1a治疗的复发缓解型多发性硬化患者补充胆钙化醇48周未促进NEDA-3状态。
临床怎么用
- 对于接受皮下干扰素β-1a治疗的复发缓解型多发性硬化患者,高剂量维生素D3添加治疗不应以改善NEDA-3为主要目的。
- 高剂量维生素D3可能对减少MRI新发活动病灶有益,但需结合个体情况并关注其安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the phase II, randomized, double-blind, placebo-controlled Supplementation of Vigantol Oil versus Placebo Add-on in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Receiving Rebif Treatment (SOLAR) study (NCT01285401), we assessed the efficacy and safety of add-on vitamin D3 in patients with RRMS. METHODS: Eligible patients with RRMS treated with SC interferon-β-1a (IFN-β-1a) 44 μg 3 times weekly and serum 25(OH)D levels <150 nmol/L were included. From February 15, 2011, to May 11, 2015, 229 patients were included and randomized 1:1 to receive SC IFN-β-1a plus placebo (n = 116) or SC IFN-β-1a plus oral high-dose vitamin D3 14,007 IU/d (n = 113). The revised primary outcome was the proportion of patients with no evidence of disease activity (NEDA-3) at week 48. RESULTS: At 48 weeks, 36.3% of patients who received high-dose vitamin D3 had NEDA-3, without a statistically significant difference in NEDA-3 status between groups (placebo 35.3%; odds ratio 0.93; 95% confidence interval [CI] 0.53-1.63; p = 0.80). Compared with placebo, the high-dose vitamin D3 group had better MRI outcomes for combined unique active lesions (incidence rate ratio 0.68; 95% CI 0.52-0.89; p = 0.0045) and change from baseline in total volume of T2 lesions (difference in mean ranks: -0.074; p = 0.035). CONCLUSIONS: SOLAR did not establish a benefit for high-dose vitamin D3 as add-on to IFN-β-1a, based on the primary outcome of NEDA-3, but findings from exploratory outcomes suggest protective effects on development of new MRI lesions in patients with RRMS. CLINICALTRIALSGOV IDENTIFIER: NCT01285401. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with RRMS treated with SC IFN-β-1a, 48 weeks of cholecalciferol supplementation did not promote NEDA-3 status.
引用
- Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019. PMID: 31594857. doi:10.1212/WNL.0000000000008445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。